Markel Stacy 4

What Happened

• Markel Stacy, Chief People Officer of Nuvation Bio (NUVB), exercised stock options to acquire a total of 125,000 shares (90,380 at $1.87 and 34,620 at $1.74) on 2026-06-23 and sold 125,000 shares in an open-market transaction the same day. The sale generated $753,188 (weighted-average $6.03/share); the reported cost to acquire the shares was $229,250 ($169,011 + $60,239), implying approximate gross proceeds of $523,938 before taxes/fees.
• The filing also lists derivative conversions/dispositions at $0 for the same option share amounts, reflecting conversion/treatment of the exercised awards (see Key Details).

Key Details

• Transaction date: 2026-06-23; Form filed 2026-06-24 (timely).
• Exercises: 90,380 shares @ $1.87 (cost $169,011) and 34,620 shares @ $1.74 (cost $60,239).
• Sale: 125,000 shares sold @ weighted-average $6.03; prices ranged $6.00–$6.085 (per filing).
• Sale proceeded under a 10b5-1 trading plan dated Dec 4, 2025 (Footnote F1). Weighted-average price noted in Footnote F2; full price breakdown available on request.
• Vesting info: the exercised options include awards with vesting schedules noted in the filing (Footnotes F3 and F4).
• Shares owned after transaction: not specified in the supplied summary of the filing.

Context

• This was an exercise of vested options followed by an immediate sale of shares — effectively monetizing option value (often called a cashless exercise/sell-off pattern). The sale was executed under a pre-established 10b5-1 plan, which is a routine way insiders sell shares on a set schedule and does not by itself indicate insider sentiment.